Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
about
Pathogen-reduced platelets for the prevention of bleedingCurrent methods for the reduction of blood-borne pathogens: a comprehensive literature reviewPathogen inactivation technologies for cellular blood components: an updatePlatelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.Platelet transfusions for patients with haematological malignancies: who needs them?Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system.Inverse probability weighted estimating equations for randomized trials in transfusion medicine.Pathogen reduction technologies: The pros and cons for platelet transfusion.Component pathogen inactivation: a critical review.Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period.A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States.The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions.Update on the use of pathogen-reduced human plasma and platelet concentrates.Pathogen-reduced platelets for the prevention of bleeding.Peculiarities of studying the effects of pathogen reduction technologies on platelets.Will pathogen reduction of blood components harm more people than it helps in developed countries?Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations.Effect of extending the platelet storage time on platelet utilization: predictions from a mathematical model of prophylactic platelet support.Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment.Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function."Humanized" stem cell culture techniques: the animal serum controversyDevelopment of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates.Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates.Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow.Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets.In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates.In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set.In response to the comment by Hechler et al.: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials.Response to "An unbalanced study that lacks power: a caution about IPTAS".Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.Oxygen measurements in platelet fluids - a new non-invasive method to detect bacterial contaminations in platelets.A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
P2860
Q24199041-270D4CF0-EE03-4D5A-99E8-303F2036D494Q26996247-C67C313E-95B9-4E5E-A552-BB9676F54EE5Q28655769-B930A962-5037-4D6F-8E5E-AF4B058AB9F6Q33369830-0C2BAE17-E85B-481F-816B-D3FA32E88114Q33370536-4F5B45B4-423D-4592-8862-7D5595699D8FQ33395509-6E607DB6-1634-4DFA-855E-11559C6E5BD1Q33397396-71CA53B5-3AFE-4F11-BD6B-C036854BD0DEQ33407359-0AC6C33D-C25C-49D2-8D14-9E1353347A35Q33441980-7233E518-2265-4309-8C3F-1C96562FB691Q34310415-03DDD7B2-1E6D-47EC-A3B6-6F8E4ED55C08Q35095646-EE94D038-2F10-4FC2-967D-7E9CB8525B79Q36402628-84D104D7-0051-47DC-A451-945C93E24B9AQ37013124-84E2049B-111B-4DB0-93D6-0495B938E26EQ37789774-2BDF5F16-3603-4300-9271-4D7D63C19F66Q38052141-5F05D8ED-1198-4D26-B2D2-4003C94A63A8Q38073018-24238AAC-0943-4891-B86C-F411BE827248Q38109665-EFB76FA5-DC82-4E8B-B65E-EF8913D14D7EQ38653240-DEC85E64-9272-4F25-8387-D427BF06CB00Q38812483-62DD214A-694D-4A86-B0A7-1044CDF4D2A4Q38831832-FD20D9AB-8F2D-410D-86E9-47C2EA39C464Q39521376-D1BFA015-EF40-4299-82C7-EB9FF612F749Q40223897-4F78BF45-4F94-4CEA-B8DB-952B4899872CQ40318288-08401687-9031-4110-BB2A-19C93597135AQ40424356-8E596FF2-A4F2-4E6D-A2FE-DFD3039CDCDCQ40427955-A0B57ABD-DB4D-4957-9E2A-8B38878B6B7EQ41627658-5070D4CE-34C7-4918-B451-BAFCFFA77EECQ42735346-6FA46932-3380-4EC9-91FD-376AC20D82D4Q42792674-4E6425B2-4A4A-4899-929A-34998905D115Q44827919-6323DE13-2EC4-4068-89D8-23CCD3BD3BF9Q45303414-94939FD2-BB6F-4F84-83B1-58B889ED20ECQ45501605-7A5ACB3A-6228-4834-BA7F-489238C8E73EQ46115563-FAE82F54-15B9-4F5C-83A7-9495FA5B4054Q46743693-DDCDC456-A29A-4D88-A816-20BA54B57837Q46906945-1C83DF06-A07D-4D70-A276-5C4507EE76E4Q47129210-DD8654DB-8028-4348-9959-2828E079B44BQ47799625-AE5A00A4-31C2-41C3-B8F4-1219078FC0E6Q50227054-3BC13BA8-FE55-4FD9-A7F9-0F0564F47F16Q50499990-4B3480C2-F2A3-4E96-A37A-35D648C9BC94Q50514107-8B04E9F0-E78A-447A-9886-3B490D8AEA7FQ50542143-2211CBF8-4011-4AF8-9BD8-A222F2D8C6E3
P2860
Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Therapeutic efficacy and safet ...... h an optimized integrated set.
@ast
Therapeutic efficacy and safet ...... h an optimized integrated set.
@en
type
label
Therapeutic efficacy and safet ...... h an optimized integrated set.
@ast
Therapeutic efficacy and safet ...... h an optimized integrated set.
@en
prefLabel
Therapeutic efficacy and safet ...... h an optimized integrated set.
@ast
Therapeutic efficacy and safet ...... h an optimized integrated set.
@en
P2093
P2860
P1433
P1476
Therapeutic efficacy and safet ...... h an optimized integrated set.
@en
P2093
Bruno Lioure
Daniel Kientz
Harald Klüter
Jan Hastka
Jin-Sying Lin
Jocelyne Flament
Karin Janetzko
Martine Michel
Maureen G Conlan
P2860
P304
P356
10.1111/J.1537-2995.2005.00550.X
P577
2005-09-01T00:00:00Z